There's Still No FDA-Approved Pill for Meth or Cocaine Addiction. Here's What Fills the Gap.

If you walk into treatment for opioid use disorder today, there’s methadone, buprenorphine, naltrexone — real, FDA-approved medications with decades of evidence behind them. Walk in for methamphetamine or cocaine, and there’s nothing to prescribe. Not one approved drug.

Medicine solved this problem for opioids and alcohol, and simply hasn’t for the stimulant class that’s now involved in most overdose deaths in the country.

The numbers explain why this isn’t a fringe gap. Methamphetamine was involved in roughly 35,000 overdose deaths in 2023 alone — about a third of the total — and cocaine in another 30,000. Look at surveillance data from 2021 through mid-2024 and stimulants show up in close to 60% of all overdose deaths, nearly half of them alongside an opioid. And when someone overdoses on a stimulant, naloxone — the one harm-reduction tool everyone now knows to carry — does nothing. A stimulant overdose is a cardiovascular event: a racing, straining heart, not a slowing breath. There isn’t even a standard medical detox protocol for it, the way there is for opioids or alcohol.

The FDA’s own 2023 draft guidance calling on drugmakers to develop stimulant medications was, as Acuity News put it, “an unusual step that signaled how wide the therapeutic hole has become.” Dozens of compounds have been tested in the years since. None has cleared the bar for approval.

What actually works, per the evidence that exists, isn’t a pill at all — it’s contingency management: paying people small, escalating incentives for verified, drug-free urine tests. It has the strongest evidence base of anything tried for stimulant use disorder. It’s also chronically underfunded and, in some states, tangled in old anti-kickback rules that treat a $10 gift card for a clean test with more suspicion than the absence of any treatment at all.

If you’re a case manager or a program director, the useful move this week isn’t waiting on a drug pipeline that’s produced nothing in twenty years of trying. It’s checking whether your state Medicaid plan or opioid settlement dollars can fund a contingency management pilot now, while the federal guidance on incentive limits is still workable. The treatment gap for stimulants isn’t a science problem anymore so much as it’s a “will anyone pay for the thing that already works” problem.